PILA PHARMA: MANAGEMENT TEAM COMMENTS ON OUTCOME OF TO2 WARRANTS
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, today announced the outcome of exercise in warrants of...
REG
MAR
PILA PHARMA ANNOUNCES THE OUTCOME IN THE EXERCISE OF WARRANTS OF SERIES TO2
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEA...
REG
PILA PHARMA: Upcoming last days for exercise with the warrants of series TO2
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEA...
PILA PHARMA: CEO REPORT INTERVIEW AND Q&A ON CLINICAL PLANS, TO2 WARRANTS AND MORE, AVAILABLE FOR REPLAY NOW
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, invites to a live online interview and Q&A.
CEO Gustav...
PILA PHARMA: INVITATION TO LIVE H2 / YEAR-END REPORT INTERVIEW AND Q&A TODAY AT 14:00 CET
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, invites to a live online interview and Q&A.
CEO Gustav...
REG
PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s year-end report for the period January - December 2025.
The report can be found on the Company´s website:
https://pilapharma.com/financial-reports/SUMMARY OF YEAR-END REPORT
SECOND HALF YEAR (1 JULY- 31 DECEMBER 2025)
• Operating i...
REG
MAR
PILA PHARMA PREPARES CLINICAL TRIAL APPLICATION IN RARE DISEASE ERYTHROMELALGIA
PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announces that...
REG
THE EXERCISE PRICE FOR THE WARRANTS OF SERIES TO2 IN PILA PHARMA HAS BEEN DETERMINED TO SEK 1.50 AND THE EXERCISE PERIOD COMMENCES TODAY
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, completed a rights issue of units d...
REG
PILA PHARMA ACCELERATES THE PUBLICATION OF THE INTERIM REPORT OF THE SECOND HALF OF 2025
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announced that it will publis...
PILA PHARMA: INVITATION TO LIVE Q&A TODAY, JANUARY 27, REGARDING PRECLINICAL STUDIES AND UPCOMING CLINICAL STUDIES
PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today hosts an onlin...
REG
MAR
PILA PHARMA SIGNS WITH NEW CLINICAL CRO TO PREPARE FOR CLINICAL PHASE IN OBESITY AFTER PRECLINICAL OBESITY STUDIES
Malmö, 26 January 2026
PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibito...
PILA PHARMA: CEO PARTICIPATED IN SWEDISH INVESTMENT PODCAST MARKET MAKERS
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, is delighted to...
PILA PHARMA: ANALYST GROUP INITIATES NEW EQUITY RESEARCH COVERAGE - BASE CASE TARGET OF SEK 6.30
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, is deepening its...
PILA PHARMA: INVITED TO PRESENT AT BIOTECH SHOWCASE / J.P MORGAN HEALTHCARE WEEK IN SAN FRANCISCO, JANUARY 13, 2026
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, today shares tha...
PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, today announces...
REG
MAR
PILA PHARMA: PRECLINICAL STUDIES OF XEN-D0501 IN OBESITY INITIATED
PILA PHARMA AB (publ) (FN STO: PILA) today announces that it has initiated the planned preclinical studies in obesity. The aim is to demonstrate preclinical proof-of-concept of...
PILA PHARMA ANNOUNCES PRE-CLINICAL OBESITY AND AMYLIN SPECIALIST PROFESSOR THOMAS LUTZ TO JOIN AS SCIENTIFIC ADVISER
PILA PHARMA AB (publ) (FN STO: PILA) informs that Professor Thomas Lutz DVM, PhD, University of Zurich, Switzerland is now joining PILA PHARMA's Scientific Advisory Board.
PILA PHARMA: UPCOMING PARTICIPATION IN OBESITYWEEK AND AMERICAN HEART ASSOCIATION CONVENTION
PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, informs of its p...
Om PILA PHARMA
Prenumerera
Få löpande information från PILA PHARMA via e-post.
Handelsinformation
Kurs 1,18 SEK (2026-02-26)
Förändring −67,85% (2025-02-26)